Two oral therapeutics specialists bag a combined $140M via IPO, VC funding

Although fancy technology is a big draw in drug delivery, the simple pill holds allure, at least as a replacement for dreaded needles or cumbersome intravenous infusions. Chiasma sold 1 million more shares than it originally planned en route to an IPO that raised $102 million. The developer of oral drugs to treat orphan diseases that are being treated by injectables sold 6.4 million shares for $16, above the expected price range. And Protagonist Therapeutics, the developer of an oral peptide drug aimed at irritable bowel disease, just completed a $40 million VC round, which included life science investment firms and strategic players J&J Innovation and Lilly Ventures. More about Chiasma's IPO | More about Protagonist Therapeutics from FierceBiotech

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.